-
Well back to the drawing board to gather up some additional data. We live in a world of data today, overloaded data for that matter, and decisions just are not as simple as they used to be. With all the additional side effects coming to light the FDA appears to be taking the same stance as...
-
More additional affiliations for the FDA to gather information. In the news recently have been other agreements with companies such as Blue Cross and others who will be providing data to also study the effects of drugs through medical record information in their files, based on claims, etc. No...
-
The meaning of advantage is below. Who knows what might be uncovered next as this may or may not be just a Merck issue, but as documents and other items of years past surface, this is what we have, sell, sell, sell, and it's perhaps not unlikely that some of these items and issues could exist...
-
Does this say that the FDA is perhaps not as trusted as we might like the agency to be? On the other hand is it possible to entrust any agency to this level today, and that might be more to the point. There are so many areas that need to come to focus and with all the information we have...
-
Right now according to the Wall Street Journal, patients who have enjoyed an open relationship are worried that this could all change under management from Roche. Is bigger always better? Recently in the news Genentech is not happy with the offer and may hold out for more. Anyone that...
-
As marketing intensity increases, there are some strange bedfellows emerging and who knows what could be the next affiliation we may read about? Ask your Abbott representative about Crestor. BD Under the terms of the agreement, Abbott will obtain the non-exclusive right to promote CRESTOR...
-
One reason stated is convenience, more on every corner, like the gas stations. To take advantage of some of the other low cost benefits, there may be a longer driving distance. A while back I had a conversation with someone from CVS, and there are shoppers who visit every store, one for a...
-
Some things in sales don't change no matter what field you are in and Pharma is no different, sales are made by building relationships, in other words, people do business with people they like, so the peer articles maybe could be just a little off target. I spent over 20 years in outside sales...
-
The patent is stated not to expire until 2010 and this will put a 30 hold at the FDA to grant approval. This one should prove interesting to follow and see where the infringement occurs. BD LONDON -(Dow Jones)- Sanofi-Aventis SA (SNY) has launched a legal action against Canadian generic drugmaker...
-
Discussed here is the recent law in Massachusetts relative to gifts, etc. just recently passed. Being the CEO of BIO, the biotech industry trade group, of course there's an interest in not having funds diminished, but also addresses the interest of the public. With all the recent Pharma...